VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

S. F. Powell, M. R. Patel, J. Merchan, J. Strauss, T. P. Cripe, M. O. Old, R. M. Diaz, M. Reckner, B. Brunton, N. Packiriswamy, D. Upreti, L. Suksanpaisan, R. Vandergaast, R. Khan, S. J. Russell, K. W. Peng, A. S. Bexon

Research output: Contribution to journalArticle

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)viii439
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Powell, S. F., Patel, M. R., Merchan, J., Strauss, J., Cripe, T. P., Old, M. O., Diaz, R. M., Reckner, M., Brunton, B., Packiriswamy, N., Upreti, D., Suksanpaisan, L., Vandergaast, R., Khan, R., Russell, S. J., Peng, K. W., & Bexon, A. S. (2018). VSV-IFNβ-NIS intratumoral (IT) injection: A first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii439. https://doi.org/10.1093/annonc/mdy288.108